Private: Gallery Post #1

04

Feb2015

PMPRB Update – January 2015 NEWSletter

PMPRB The PMPRB has released its January 2015 NEWSletter Topics covered in the NEWSletter include: Final 2014 CPI-Based Price-Adjustment Factors: The final CPI figures for 2014 are now available. Of note: The actual CPI-based price-adjustment factor for 2 year (2012) and 3 year (2011) are lower than forecast. As a result, some manufacturers/patentees may ... Read More

14

Jan2015

Drug products undergoing evaluation for the June 2015 “Liste des médicaments”

QUEBEC L’Institut national d’excellence en santé et en services sociaux (INESSS) has released the list of drug products submitted for the June 2015 “Liste des médicaments.” Health professionals, citizens and patients and their associations and groups have until ... Read More

05

Jan2015

CDEC Final Recommendation for Inflectra Posted

Common Drug Review The Canadian Agency for Drugs and Technologies in Health posted the Canadian Drug Expert Committee (CDEC) final recommendation for its first review of a subsequent entry biologic on its website yesterday. Below is an excerpt from the CDEC Final Recommendation. Recommendation: ... Read More

14

Nov2014

PMPRB Has Released its October 2014 NEWSletter

Included in this edition are: PMPRB Town Hall Meeting PMPRB Staff held a Town Hall meeting on October 1 at the Ottawa Convention Centre. Discussions involved PMPRB Staff taking a fresh look at the organization’s vision and mandate, potential new strategic priorities for the PMPRB and how to operationalize them moving forward. ... Read More

06

Nov2014

Proposed Regulation Amendments to Establish a Pricing Framework for Generic Products

ONTARIO Proposed Regulation Amendments to Establish a Pricing Framework for Generic Products An Ontario Public Drug Programs Executive Officer Communication published on November 5, 2014 invites stakeholder comments on proposed amendments to O. Reg. 201/96 under the Ontario Drug Benefit Act. The proposed amendments would establish a pricing framework for ... Read More

03

Nov2014

PDCI Career Opportunity

Date Posted: November 3, 2014 Location: Ottawa, Ontario Job Title: Pricing & Market Access Associate Reports To: Director, Pricing & Market Access Employment Type: Full-time Website: pdci.ca/about-us/careers/ For more information regarding this position or any other career opportunities with PDCI, please visit our careers page.

03

Nov2014

Voluntary Compliance Undertaking of Valeant Canada LP to PMPRB

PMPRB The Chairperson of the Board has approved a Voluntary Compliance Undertaking submitted by Valeant Canada LP regarding the price of Lodalis (colesevelam hydrochloride). For more information regarding the VCU, please consult the PMPRB website.

24

Oct2014

Patented Medicines Prices Review Board (PMPRB) Outreach Sessions

The next PMPRB OUTREACH Sessions will be held on Tuesday, December 2, 2014 in Montreal, followed by Wednesday, December 3, 2014 in Toronto. Rumoured topics to be covered include: Changes to current international price source formularies referenced by Board Staff (specifically Germany) Supplementary price sources Updates on Form 2 regulatory amendments undergoing Canada Gazette ... Read More

22

Oct2014

Meetings with Manufacturers for the June 2015 “Liste des médicaments”

QUEBEC Meetings with Manufacturers for the June 2015 “Liste des médicaments” As part of the June 2015 updates to the “Liste des medicaments,” INESSS will meet with manufacturers who have made submissions before the deadline. These meetings with take place between December 15-19, 2014 and January 5-9, 2015 inclusively and will cover: Discussions on ... Read More

16

Oct2014

IBM “Pan Canadian Drugs Negotiation Report” Now Available

Pan-Canadian Pharmaceutical Alliance (pCPA) has posted the IBM Report on its website  The much anticipated IBM report (entitled “Pan Canadian Drugs Negotiation Report”) has now been posted on the pCPA website. The objectives of the IBM engagement include: Recommending options for the development of a permanent model that will facilitate negotiations for brand ... Read More